Corcept Therapeutics Incorporated

Financials

Flusso di cassa derivante dalle attività operative 59.83 M5.13 M43.94 M54.48 M38.45 M 142 M Flussi di cassa derivanti dalle attività di investimento -64.36 M-3.17 M70.13 M14.64 M-11.84 M 69.76 M Liquidità derivante dalle attività di finanziamento -4.56 M-39.8 M-102.93 M-46.41 M-31.22 M -220.37 M Liquidità libera 59.71 M5.02 M43.88 M54.48 M38.4 M 141.78 M

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated

Notizie

Lifyorli di Corcept riduce del 35% il rischio di morte nel cancro ovarico

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Il dirigente di Corcept Therapeutics Guyer vende azioni per 819.000$

Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) (NASDAQ:CORT)

Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Wolfe Research alza il rating su Corcept Therapeutics dopo l’approvazione FDA

La FDA approva Lifyorli di Corcept per il cancro ovarico

Le azioni Corcept Therapeutics salgono dopo approvazione FDA

Why Corcept's Ovarian Cancer 'Hail Mary' Might Actually Land (NASDAQ:CORT)

Le azioni di Corcept Therapeutics salgono dopo l’acquisto di azioni da parte di un amministratore